Immunology of multiple sclerosis

Current Allergy and Asthma Reports

Volumn 7, Issue 4, 2007, Pages 285-292

  Pender, Michael P ^a   Greer, Judith M ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AUTOANTIBODY; AUTOANTIGEN; BETA INTERFERON; GANGLIOSIDE; GLATIRAMER; HLA ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN ASSOCIATED OLIGODENDROCYTIC PROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEIN; NATALIZUMAB; OLIGODENDROCYTE SPECIFIC PROTEIN; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; CELL SURVIVAL; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DEMYELINATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; GERMINAL CENTER; HEREDITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; LYMPH FOLLICLE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE INJURY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VIRUS INFECTION; VIRUS PATHOGENESIS;

AUTOANTIBODIES; AXONS; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GANGLIOSIDES; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HLA-D ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS; MYELIN PROTEINS; T-LYMPHOCYTES;

EID: 34250708338     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0043-x     Document Type: Review

References (51)

1. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
2. Gold R, Linington C, Lassmann H: Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
3. Brück W: The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005, 252(Suppl 5):v3-v9.
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al.: Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
5. Kutzelnigg A, Rauschka H, Stadeimann C, et al.: Pathological substrate of disease progression in multiple sclerosis. J Neuroimmunol 2004, 154:189.
6. Serafini B, Rosicarelli B, Magliozzi R, et al.: Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
7. Armengol MP, Juan M, Lucas-Martín A, et al.: Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 2001, 159:861-873.
8. Freedman MS, Thompson EJ, Deisenhammer F, et al.: Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005, 62:865-870.
9. Oksenberg JR, Barcellos LF: Multiple sclerosis genetics: leaving no stone unturned. Genes Immun 2005, 6:375-387.
10. Barcellos LF, Sawcer S, Ramsay PP, et al.: Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15:2813-2824.
11. Greer JM, Pender MP: The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRß1 chain is associated with the clinical course of multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:656-662.
12. McCombe PA, Chalk JB, Pender MP: Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. J Neurol Sci 1990, 97:163-171.
13. Henderson RD, Bain CJ, Pender MP: The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000, 7:434-437.
14. Bias WB, Reveille JD, Beaty TH, et al.: Evidence that autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet 1986, 39:584-602.
15. Barcellos LF, Kamdar BB, Ramsay PP, et al.: Clustering of autoimmune diseases in families with a high risk for multiple sclerosis: a descriptive study. Lances Neurol 2006, 5:924-931.
16. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
17. Greer JM, Csurhes PA, Cameron KD, et al.: Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997, 120:1447-1460.
18. Pender MP, Csurhes PA, Greer JM, et al.: Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000, 165:5322-5331.
19. Raine CS, Cannella B, Hauser SL, Genain CP: Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999, 46:144-160.
20. Lucchinetti C, Brück W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
21. Greer JM, Pender MP: Antibodies specific for myelin proteolipid protein are of potential pathogenic relevance in myelin opsonization in multiple sclerosis. Clin Immunol 2005, 115(Suppl 1):S91.
22. Zhou D, Srivastava R, Nessler S, et al.: Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:19057-19062.
23. Sadatipour BT, Greer JM, Pender MP: Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998, 44:980-983.
24. Pender MP, Csurhes PA, Wolfe NP, et al.: Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 2003, 10:63-66.
25. Marconi S, Acler M, Lovato L, et al.: Anti-GD2-like IgM autoreactivity in multiple sclerosis. Mult Scler 2006, 12:302-308.
26. Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
27. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
28. Villar LM, Masjuan J, González-Porqué P, et al.: Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003, 53:222-226.
29. Cepok S, Jacobsen M, Schock S, et al.: Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001, 124:2169-2176.
30. Qin Y, Duquette P, Zhang Y, et al.: Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998, 102:1045-1050.
31. Cepok S, Zhou D, Srivastava R, et al.: Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005, 115:1352-1360.
32. Williamson RA, Burgoon MP, Owens GP, et al.: Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A 2001, 98:1793-1798.
33. Collard RC, Koehler RP, Mattson DH: Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997, 49:857-861.
34. Villar LM, Sádaba MC, Roldán E, et al.: Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
35. Correale J, Fiol M, Gilmore W: The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006, 67:652-659.
36. Pender MP: Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24:584-588.
37. Pender MP: Epstein-Barr virus and autoimmunity. In Infection and Autoimmunity. Edited by Shoenfeld Y, Rose NR. Amsterdam: Elsevier; 2004:163-170.
38. Ascherio A, Munch M: Epstein-Barr virus and multiple sclerosis. Epidemiology 2000, 11:220-224.
39. Wandinger K-P, Jabs W, Siekhaus A, et al.: Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55:178-184.
40. Pohl D, Krone B, Rostasy K, et al.: High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006, 67:2063-2065.
41. Thacker EL, Mirzaei F, Ascherio A: Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006, 59:499-503.
42. Levin LI, Munger KL, Rubertone MV, et al.: Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
43. Pender MP: Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998, 351:978-981.
44. Pender MP, Nguyen KB, McCombe PA, Kerr JFR: Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 1991, 104:81-87.
45. Tabi Z, McCombe PA, Pender MP: Apoptotic elimination of Vβ8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vβ8.2+ encephalitogenic T cells. Eur J Immunol 1994, 24:2609-2617.
46. Pender MP, Rist MJ: Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001, 36:137-144.
47. James JA, Kaufman KM, Farris AD, et al.: An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
48. Polman CH, O'Connor PW, Havrdova E, et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
49. Berger JR, Koralnik IJ: Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005, 353:414-416.
50. Pender MP, Wolfe NP: Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Intern Med J 2002, 32:554-563.
51. Diamond MC, Scheibel AB, Elson LM: The Human Brain Coloring Book. New York: HarperCollins; 1985.